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In Brief
Tencerova et al. show that in human
obesity, BM-MSCs exhibit a
hypermetabolic state defined by
upregulation of insulin signaling with
enhanced adipogenesis and increased
intracellular reactive oxygen species
(ROS), leading to a senescence bone
microenvironment contributing to bone
fragility. Moreover, increased abundance
of IR+ and LEPR+ BM-MSCs is
characteristic of this phenotype, with an
activated metabolic rate in obese
subjects.
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Obesity is associated with increased risk for fragility
fractures. However, the cellular mechanisms are un-
known. Using a translational approach combining
RNA sequencing and cellular analyses, we investi-
gated bone marrow stromal stem cells (BM-MSCs)
of 54 men divided into lean, overweight, and obese
groups on the basis of BMI. Compared with BM-
MSCs obtained from lean, obese BM-MSCs ex-
hibited a shift of molecular phenotype toward
committed adipocytic progenitors and increased
expression of metabolic genes involved in glycolytic
and oxidoreductase activity. Interestingly, compared
with paired samples of peripheral adipose tissue-
derived stromal cells (AT-MSCs), insulin signaling of
obese BM-MSCs was enhanced and accompanied
by increased abundance of insulin receptor positive
(IR+) and leptin receptor positive (LEPR+) cells in
BM-MSC cultures. Their hyper-activated metabolic
state was accompanied by an accelerated senes-
cence phenotype. Our data provide a plausible
explanation for the bone fragility in obesity caused
by enhanced insulin signaling leading to accelerated
metabolic senescence of BM-MSCs.INTRODUCTION
Obesity is a major health problemworldwide, and besides meta-
bolic complications such as insulin resistance, type 2 diabetes2050 Cell Reports 27, 2050–2062, May 14, 2019 ª 2019 The Author(s
This is an open access article under the CC BY license (http://creative(T2D), and liver steatosis, bone fragility is increasingly recog-
nized (Napoli et al., 2017). Recent epidemiological studies have
reported an association between obesity and increased risk for
fragility fractures at several anatomical sites (Gonnelli et al.,
2014). This is paradoxical because obesity is associated with
normal or increased bone mass and is traditionally thought to
be protective against fragility fractures because of higher bone
mass caused by increased mechanical loading on the skeleton
and higher estrogen levels (Wardlaw, 1996). Obesity is associ-
ated with increased bone marrow adipose tissue (BMAT) that al-
ters bone marrow (BM) composition and thus may change bone
architecture and bone material properties that contribute to
reduced bone quality (Ambrosi et al., 2017; Boskey and Imbert,
2017; Naveiras et al., 2009; Rubin et al., 2007). However, the
cellular mechanisms underlying these changes are not known.
BMAT originates from BM stromal (also known as skeletal or
mesenchymal) stem cells (BM-MSCs), which also give rise to
osteoblastic bone-forming cells (Gimble et al., 2006). The differ-
entiation potential of BM-MSCs is tightly regulated via several
factors present in the BM microenvironment, including secreted
proteins and hormones (Tencerova and Kassem, 2016). Some of
these factors (e.g., secreted frizzled-related protein [sFRP-1] and
legumain [LGMN]) determine the commitment of BM-MSCs into
the adipocyte or osteoblast lineages (Abdallah and Kassem,
2012; Jafari et al., 2017). Under steady-state conditions, there
is a balance between BM-MSCs and their committed progeni-
tors. However, this balance alters with aging and osteoporosis
because of microenvironmental changes (Kassem and Marie,
2011).
Similar to aging, the BM microenvironment undergoes signifi-
cant metabolic changes in obesity. Previous studies have
reported increased BMAT and changes in immune cell differen-
tiation and level of inflammation (Adler et al., 2014; Bredella et al.,).
commons.org/licenses/by/4.0/).
Table 1. Clinical and Biochemical Characteristics of Study
Participants
Clinical and
Biochemical Data Lean (n = 19)
Overweight
(n = 15)
Obese
(n = 20)
Age (years) 31 ± 3 32 ± 3 37 ± 2a
Weight (kg) 75.2 ± 1.8 95.4 ± 2.7b 117.2 ± 3.2c
Height (cm) 181.0 ± 1.1 184.1 ± 1.9 179.9 ± 1.3
BMI (kg/m2) 22.9 ± 0.3 28.0 ± 0.4b 36.1 ± 0.8c
Waist (cm) 83.0 ± 1.2 100.0 ± 2.7b 118.9 ± 2.6c
Hip (cm) 95.1 ± 0.9 106.1 ± 1.6b 113.9 ± 1.2c
WHR 0.87 ± 0.01 0.94 ± 0.02d 1.04 ± 0.02c
Fasting glucose
(mmol/L)
5.2 ± 0.1 5.4 ± 0.1 5.8 ± 0.1c
Fat free mass (kg) 63.3 ± 1.2 72.0 ± 2.0b 76.0 ± 1.6c
Fat mass (kg) 11.9 ± 0.8 23.4 ± 1.2b 41.2 ± 2.1c
Android/gynoid
fat ratio
0.40 ± 0.02 0.46 ± 0.04e 0.73 ± 0.06c
HDL cholesterol
(mmol/L)
1.18 ± 0.04 1.11 ± 0.08 1.01 ± 0.04f
LDL cholesterol
(mmol/L)
2.66 ± 0.15 3.07 ± 0.25 3.00 ± 0.11a
Total cholesterol
(mmol/L)
4.29 ± 0.17 4.75 ± 0.28 4.77 ± 0.16a
Triglycerides
(mmol/L)
1.00 ± 0.10 1.24 ± 0.17 1.81 ± 0.33a
PTH (pmol/L) 3.5 ± 0.3 3.8 ± 0.5 3.9 ± 0.4
25-hydroxy
vitamin D (nmol/L)
62.4 ± 5.2 57.9 ± 6.0 50.0 ± 4.2
Leukocytes (109/L) 5.6 ± 0.3 5.8 ± 0.3 6.7 ± 0.4a
HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTH, para-
thyroid hormone; WHR, waist-to-hip ratio.
ap < 0.05, lean versus obese (two-tailed unpaired Student’s t test).
bp < 0.001, lean versus overweight.
cp < 0.001, lean versus obese (two-tailed unpaired Student’s t test).
dp < 0.01, lean versus overweight.
ep < 0.05, lean versus overweight.
fp < 0.01, lean versus obese (two-tailed unpaired Student’s t test).2011; Doucette et al., 2015; Tencerova et al., 2018). Obesity is
also associated with hyperinsulinemia. Insulin signaling is a
nutrient-sensing pathway regulating whole-body energy meta-
bolism but is also associated with a senescence phenotype in
different tissues (Anisimov, 2003; LaFever and Drummond-Bar-
bosa, 2005). Depletion of insulin receptor (IR) in adipose tissue
(AT) protects from obesity-induced insulin resistance and in-
creases lifespan in mice (Bl€uher et al., 2003). In the present
study, we hypothesized that obesity induces an accelerated
senescence phenotype in the BM microenvironment and results
in changes in the cellular composition of BM-MSCs.
Disease states lead to tissue dysfunction through changes in
cellular composition. The effects of obesity on the cellular
composition of BM and BM-MSCs have not been studied.
Recent lineage-tracing studies have identified a number of
BM-MSC lineage markers (Ambrosi et al., 2017; Chan et al.,
2015; Post et al., 2008; Zhou et al., 2014). Zhou et al. (2014) iden-
tified leptin receptor (LEPR) as a marker of adult murine BM-MSCs. LEPR signaling promotes adipogenesis in mouse BM-
MSCs (Yue et al., 2016). In human BM-MSCs, LEPR expression
is upregulated with aging (Laschober et al., 2009). Furthermore,
IR is another cell surface marker determining self-renewal and
regulation of differentiation potential of the stem cells (Xia
et al., 2015), as demonstrated in peripheral AT-derived stromal
cells (AT-MSCs) and hematopoietic, intestinal, and neuronal
stem cells (Andres et al., 2013; Bl€uher et al., 2002; Cinti et al.,
1998; Xia et al., 2015; Ziegler et al., 2015), but its role in BM-
MSCs has not been studied.
Thus, we examined in a case-control study the presence of
intrinsic changes in cellular, molecular, andmetabolic character-
istics as well as senescence phenotype of BM-MSCs in obese
subjects.
RESULTS AND DISCUSSION
Obesity-Associated Increase in Bone Mass Is
Accompanied by Low Bone Turnover
To investigate whether obesity affects the cellular and molecular
phenotype of BM-MSCs, we enrolled 54 healthymen subdivided
into groups of lean, overweight (OW), and obese on the basis of
BMI. Obesity-related anthropometric parameters (weight, BMI,
and waist circumference) were significantly different among the
groups (Table 1). Body composition measured using dual-en-
ergy x-ray absorptiometry (DXA) scanning showed increased
android/gynoid ratio with increasing BMI, suggesting visceral
fat accumulation (Table 1). Basal biochemical parameters re-
vealed higher levels of fasting glucose, insulin, low-density lipo-
protein (LDL) cholesterol, triglyceride, and leukocyte count in
obese compared with lean subjects. Moreover, insulin resis-
tance status, as assessed by homeostasis model assessment
of IR (HOMA-IR), was significantly different among groups,
with higher values observed with increased BMI (Table S1).
Other fasting and oral glucose tolerance test (OGTT)-based
indices of insulin sensitivity and insulin secretion showed
reduced insulin sensitivity and a compensatory increase in insu-
lin secretion with increasing BMI (Table S1). Thus, obese sub-
jects were in a pre-diabetic condition along with a state of a
low-grade inflammation demonstrated by increased circulating
levels of pro-inflammatory markers and reduced adiponectin
(Table S2), corroborating previous findings (Klimca´kova´ et al.,
2011).
We observed differences in bone mass among the groups.
DXA scanning showed significantly increase in total hip bonemin-
eral density (BMD) but no detectable differences in lumbar spine
(L1–L4) BMD in obese compared with lean subjects (Table 2). In
addition, serum biochemical markers of bone turnover were
decreased with increasing BMI (Table 2), and P1NP/CTx was
increased in obese patients (Table 2), suggesting decreased
bone turnover, similar to what has previously been reported in
obese persons, denoting the absence of selection bias (Tonks
et al., 2017). Themolecular mechanism responsible for increased
bone mass and low turnover in obesity is not clear, but a number
of hypotheses have been proposed, including higher levels of
insulin, lower levels of IGF-1, and changes in BM-MSC differenti-
ation (Hayden et al., 1995; Napoli et al., 2017; Tonks et al., 2017).
The presence of higher levels of pro-inflammatory markers isCell Reports 27, 2050–2062, May 14, 2019 2051
Table 2. Bone Mass Measurements of DXA Scan of Hip and Spine and Serum Levels of Bone Turnover Markers
Lean (n = 19) Overweight (n = 15) Obese (n = 20)
DXA Scan Data: Hip
Trochanter area (cm2) 13.2 ± 0.2 13.4 ± 0.6 13.4 ± 0.4
BMC trochanter (g) 9.7 ± 0.4 10.1 ± 0.6 10.7 ± 0.4 (p = 0.08)
BMD trochanter (g/cm2) 0.735 ± 0.025 0.750 ± 0.022 0.800 ± 0.025 (p = 0.07)
Intertrochanteric area (cm2) 24.4 ± 0.7 26.3 ± 1.0 23.6 ± 0.5
BMC intertrochanteric (g) 28.8 ± 1.0 31.3 ± 1.7 30.4 ± 0.8
BMD intertrochanteric (g/cm2) 1.19 ± 0.03 1.19 ± 0.03 1.30 ± 0.03a
Neck area (cm2) 5.8 ± 0.1 6.0 ± 0.1 5.8 ± 0.1
BMC neck (g) 5.08 ± 0.19 5.20 ± 0.24 5.33 ± 0.15
BMD neck (g/cm2) 0.88 ± 0.03 0.87 ± 0.03 0.92 ± 0.03
Total hip area (cm2) 43.4 ± 0.8 45.7 ± 1.4 42.8 ± 0.7
BMC total hip (g) 43.6 ± 1.4 46.6 ± 2.4 46.4 ± 1.2
BMD total hip (g/cm2) 1.01 ± 0.03 1.02 ± 0.03 1.09 ± 0.03a
DXA Scan Data: Spine
BMD L1–L4 (g/cm2) 1.02 ± 0.03 1.04 ± 0.03 1.07 ± 0.02
Bone Turnover Markers
P1NP (mg/L) 85.9 ± 5.9 67.7 ± 5.8b 61.9 ± 4.5c
CTX1 (ng/L) 0.75 ± 0.1 0.59 ± 0.1 0.44 ± 0.03d
P1NP/CTX1 121.5 ± 5.4 113.2 ± 4.8 145.2 ± 7.6a
Trap5b (U/L) 4.6 ± 0.4 3.5 ± 0.3b 2.7 ± 0.2d
BMC, bone mineral content; BMD, bone mineral density; CTX1, C-telopeptide of type I collagen; P1NP, procollagen type I amino-terminal propeptide;
Trap5b, tartrate-resistant acid phosphatase 5b.
ap < 0.05, lean versus obese (two-tailed unpaired Student’s t test).
bp < 0.05, lean versus overweight.
cp < 0.01, lean versus obese (two-tailed unpaired Student’s t test).
dp < 0.001, lean versus obese (two-tailed unpaired Student’s t test).usually associated with increased bone turnover, thus the pres-
ence of a low bone turnover state suggests that BM microenvi-
ronment is protected from obesity-associated inflammation.
Previous animal studies have demonstrated the absence of
high-fat diet (HFD)-induced inflammation in BM and endothelial
cell dysfunction causing BM microangiopathy and creating a
BMbarrier from the peripheral milieu (Mangialardi et al., 2013; Oi-
kawa et al., 2010; Shadduck et al., 1989; Tencerova et al., 2018).
Obesity Is Associated with Distinct Changes in
Metabolic Programming of BM-MSCs
To further study cell autonomous changes associated with
obesity, we performed RNA sequencing (RNA-seq) of BM-
MSCs isolated from lean and obese individuals. We identified
129 genes upregulated and 168 genes downregulated signifi-
cantly in BM-MSCs of obese compared with lean subjects
(Figure 1A; Figure S1A; Table S3). In order to elucidate the func-
tionality of the differentially expressed genes, we performed
Gene Ontology (GO) enrichment analyses. Genes that exhibited
higher expression in obese BM-MSCs are annotated as genes of
fat cell differentiation, osteoblast differentiation, extracellular
matrix organization, and immune systemprocesses, while genes
associated with glucose metabolic processes and response to
hypoxia were downregulated in obese subjects (Figure 1B; Fig-
ure S1B). Interestingly, the gene expression signature of obese2052 Cell Reports 27, 2050–2062, May 14, 2019BM-MSCs suggests an increased presence of committed BM-
MSC progenitors and decreased stemness.
Because GO analysis highlighted glucose metabolism to be
affected in obese BM-MSCs, we further examined the expres-
sion of a number of metabolic processes genes. We observed
increased expression of genes involved in oxidative phosphory-
lation, while genes annotated to canonical glycolysis were
repressed in obese BM-MSCs compared with lean ones (Fig-
ure 1C). About half of the genes known to be involved in the clas-
sical glycolytic pathway showed significant downregulation
(false discovery rate [FDR] < 0.1) in obese BM-MSCs (Figure 1D).
These data demonstrate that obesity is associated with changes
in the molecular signature of BM-MSCs, exhibiting reduced
glycolytic capacity and enhanced oxidative phosphorylation.
As a corollary, we found several enzymes with oxidoreductase
activity upregulated in obese BM-MSCs (e.g., LDHB, AKR1C2,
P4HA3) (Figure S1C).
BM-MSC cultures are heterogeneous with respect to differen-
tiation state and include stem cells and committed adipocytic
(AD) and osteoblastic (OB) progenitors (James et al., 2015;
Post et al., 2008). The metabolic profiles and GO analysis sug-
gest a shift in the population toward decreased stemness and
higher metabolic activity and an AD phenotype in obese BM-
MSC cultures. To further test this hypothesis, first we found
elevated expression levels of AD marker genes (e.g., PPARG,
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CEBPA, ZNF423, ADIPOQ) in obese compared with lean
BM-MSCs (Figure 1E). Second, when focusing on published
gene signatures of committed OB (mBM-MSC-Osteo) and AD
(mBM-MSC-Adipo) progenitors (Abdallah et al., 2015; Post
et al., 2008; Taipaleenma¨ki et al., 2011), we found that adipo-
cyte- but not osteoblast-associated genes were enriched in
obese BM-MSC cultures (Figure 1F). Third, we observed that
the upregulated genes in obese BM-MSCs were consistently
enriched for genes induced during adipocyte differentiation of
human BM-MSCs (hBM-MSCs) (Figure 1G) (Rauch et al., 2019;
Twine et al., 2014). Thus, bioinformatic analysis demonstrated
evidence of a shift in the molecular phenotype of cultured obese
BM-MSCs toward more committed adipocyte progenitors.
Surprisingly, we did not observe increased expression levels
of classical pro-inflammatory genes related to Toll-like receptor
and NFkB signaling (e.g., IL1B, TNF, TNFRSF11B, TNFRSF1A,
TLR4) in obese compared with lean BM-MSCs, which is oppo-
site to what has been reported in peripheral AT in obesity (Klim-
ca´kova´ et al., 2011) (Figure 1H). These data suggest that BM in
obese patients is protected from systemic inflammation and
may explain why obesity is associated with low bone turnover
and decreased bone resorption activity.
Obesity Leads to Changes in Cellular Composition of
BM-MSCs
Because RNA-seq data suggested a decreased stemness with
obesity, we investigated stem cell properties of BM-MSC
cultures obtained from lean, OW, and obese individuals. The
number of colony-forming units-fibroblast (CFUs-f), an in vitro
surrogate marker for BM-MSCs as well as the short-term prolif-
eration rate of obese BM-MSCs, decreased (Table S4; Fig-
ure 2A). The number of cells expressing common stem cell
markers of hBM-MSCs, including CD44, CD90, and CD105,
did not show any significant changes with obesity (Table S4).
However, the number of cells expressing LEPR+, IR+, and
C-X-C chemokine receptor (CXCR4+) increased (Figure 2B).
These markers were previously reported to be associated with
changes in stem cell lineage determination and regulation of im-
muno-modulatory properties of BM-MSCs (Andres et al., 2013;Figure 1. Obesity Is Associated with Enrichment of the Molecular Sign
Bone marrow stromal stem cell (BM-MSC) cultures were established from lean (n
performed on undifferentiated cells.
(A) Heatmap showing scaled expression levels from genes differentially expresse
(B) Bar plot of Gene Ontology (GO) annotations of obesity-affected genes in BM
(C) Boxplot showing the log2 fold change of genes belonging to the indicated me
(D) Schematic representation of genes enriched in glycolytic pathway expressed
(E) Boxplot showing the expression levels of adipocytic marker genes in lean and o
CEBPA, CCAAT/enhancer-binding protein alpha; ZNF423, zinc finger protein 42
(F) Bar plot representing the overlap of genes that are upregulated (orange) or dow
osteoblast progenitor cell populations as determined previously (mBM-MSCadipo
(G) Bar plot representing the overlap of genes that are upregulated (orange) or dow
the in vitro differentiation of human BM-MSCs (hBM-MSCs) to osteoblasts or adi
time points of in vitro differentiation.
(H) Boxplot showing the expression levels of classical pro-inflammatory genes in l
TNFRSF11B, tumor necrosis factor receptor superfamily member 11B; TLR1,
member 1A; TLR4, Toll-like receptor 4.
Data are presented as mean ± SEM; two-tailed unpaired Student’s t test.
See also Figure S1.
2054 Cell Reports 27, 2050–2062, May 14, 2019Miller et al., 2008; Xia et al., 2015; Zhang et al., 2016; Zhou
et al., 2014). Furthermore, obese BM-MSCs exhibited enhanced
AD differentiation capacity highlighted by the induction levels of
AD genes (PPARG, FASN, IRS1) and adipokine (ADIPOQ)
(Figure 2C) as well as oil red O staining for mature adipocytes
(Figure 2D). In addition, obese BM-MSCs showed increased
OB differentiation, measured by increased alkaline phosphatase
(ALP) activity, alizarin red staining for mineralized matrix forma-
tion, and ALPL mRNA levels (Figure 2E). Taken together, the
in vitro data corroborate the observed molecular phenotype
identified by RNA-seq and revealed enrichment of committed
progenitors in obese BM-MSC cultures. It is plausible that the
combined small number of CFU-f and increased number of
committed progenitors contribute to low bone turnover state
observed in obese subjects, as it leads to progressive failure in
the recruitment of new cells needed for bone remodeling. A
similar observation wasmade in amurinemodel of HFD-induced
obesity, in which we and other research groups reported the
presence of a decreased CFU-f number and an increased num-
ber of AD progenitors (Ambrosi et al., 2017; Tencerova et al.,
2018).
Obese BM-MSCs Maintain Insulin Responsiveness
Insulin resistance and high insulin levels are associated with
obesity, resulting in its known metabolic complications of dia-
betes and cardiovascular disease (Czech et al., 2013). Previous
studies have demonstrated the presence of an insulin-resis-
tance phenotype at the level of extramedullary adipocytes
(Rossmeislova´ et al., 2013), muscle (Petersen et al., 2007), and
liver (Perry et al., 2014) in obese subjects. However, the role of
insulin resistance in bone metabolism is not well studied. Thus,
we examined insulin signaling and responsiveness in BM-
MSCs obtained from lean and obese subjects and compared
insulin responsiveness in paired AT-MSCs established from ex-
tramedullary subcutaneous AT (SAT) (in a subgroup of ten sam-
ples per group from the original cohort of 57 subjects). Interest-
ingly, obese compared with lean BM-MSCs exhibited enhanced
insulin-stimulated activation of pAKT(S473) to total AKT, a
marker of cellular insulin responsiveness in undifferentiatedature of BM-MSCs into Adipocytic Progenitor Cells
= 10) and obese (n = 10) healthy subjects. RNA was isolated and RNA-seq was
d between BM-MSCs of lean and obese subjects (n = 10 per group).
-MSCs.
tabolic process between obese and lean BM-MSC cultures.
in lean versus obese BM-MSC cultures.
bese BM-MSCs. PPARG, peroxisome proliferator-activated receptor gamma;
3; ADIPOQ, adiponectin.
nregulated (purple) in obese BM-MSCs with gene signatures from adipocyte or
and mBM-MSCosteo, respectively) (Abdallah et al., 2015; Post et al., 2008).
nregulated (purple) in obese BM-MSCs with genes being upregulated through
pocytes. The red line shows the number of genes upregulated at the indicated
ean and obese BM-MSCs. IL1B, interleukin-1 beta; TNF, tumor necrosis factor;
Toll-like receptor 1; TNFRSF1A, tumor necrosis factor receptor superfamily
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Figure 2. Obesity Leads to Changes in the
Cellular Composition of BM-MSCs
BM-MSCs were established from lean (n = 19),
overweight (OW) (n = 15), and obese (n = 20)
subjects. The cells were examined in undifferen-
tiated state and following adipocyte differentiation
(AD) during 10 days.
(A) Short-term proliferative rate and area under the
curve (AUC) of BM-MSCs in lean, OW, and obese
subjects (n = 15–20). *p < 0.05, lean versus obese;
#p < 0.05, lean versus OW.
(B) Screening of stem cell surface marker expres-
sion, such as LEPR, IR, and CXCR4, measured
using flow cytometry in BM-MSCs isolated from
lean, OW, and obese subjects (n = 15–20). *p <
0.05, lean versus obese.
(C) Adipocyte differentiation of BM-MSCs evalu-
ated using gene expression of PPARG, FASN,
IRS1, and ADIPOQ.
(D) Oil red O staining of mature adipocytes (scale
bar, 100 mm; n = 15–20). Data are presented as
mean of fold change (F.C.) of gene expression
over undifferentiated cells ± SEM; *p < 0.05; **p <
0.01, lean versus obese AD BM-MSCs (two-tailed
unpaired Student’s t test).
(E) Osteoblast differentiation potential of the BM-
MSCs evaluated using quantification of alkaline
phosphatase (ALP) activity represented as fold
change (F.C.) over non-induced cells (day 7),
alizarin staining (scale bar, 400 mm), and gene
expression of ALPLmRNA levels (n = 15–20); **p <
0.01; ***p < 0.001, lean versus obese CT BM-
MSCs; #p < 0.05, lean versus obese OBBM-MSCs
(two-tailed unpaired Student’s t test).state, and this responsiveness was maintained following AD dif-
ferentiation (Figures 3A and 3B). On the other hand, obese AT-
MSCs from SAT exhibited impaired insulin signaling compared
with lean AT-MSCs (Figures 3C and 3D). Moreover, obese AT-
MSCs in contrast to BM-MSCs showed a higher expression level
of pro-inflammatory genes, lower expression of AD marker
genes (Figures 3E, 3F, and 1H, respectively), and decreased
number of LEPR+ and IR+ cells in obesity (Figure S2A), support-
ing previous findings of a negative effect of obesity on the reser-
voir of functionally active extramedullary AD progenitors (On˜ate
et al., 2012). Comparison of LEPR and IR expression levels be-
tween BM-MSCs and AT-MSCs revealed higher abundance of
both markers in BM-MSCs (Figures S2B and S2C), corrobo-
rating the existence of significant differences between BMAT
and peripheral AT. In addition, IR expression in BM-MSCs wasCell Rpositively correlated with clinical param-
eters such as BMI and fasting glucose,
supporting the evidence of enhanced
insulin signaling in BM-MSCs in obese
subjects (Figure S2D).
Our findings suggest that obesity in-
duces insulin resistance in peripheral AT
but maintains insulin sensitivity in BM-
MSCs. Previous animal studies have
investigated the role of insulin signalingin bone homeostasis (Ferron et al., 2010; Fulzele et al., 2010;
Wei et al., 2014) using INSR-deficient mice as a model for insulin
resistance relevant for insulin deficiency phenotype taking place
as a complication of long-standing T2D, which is different from
our clinical studywith obese subjects who exhibited insulin resis-
tance phenotype but no overt diabetes.
Moreover, the study in obese mice receiving a HFD showed
local insulin resistance in bone (Wei et al., 2014). However, insu-
lin signaling was examined in the whole-bone lysate that con-
tains heterogeneous cell populations. These observations do
not contradict our findings, as the authors did not examine
intrinsic changes in BM-MSCs, and the observed insulin resis-
tance may have been related to microenvironmental factors.
Also, the mice examined were overtly diabetic, whereas the
human subjects in our study were not. Furthermore, the studyeports 27, 2050–2062, May 14, 2019 2055
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Figure 3. Insulin Signaling Is Enhanced in
Obese BM-MSCs
The subgroup of samples of BM-MSCs and adi-
pose-derived stem cells (AT-MSCs) (lean, n = 10;
obese, n = 10) was established from the original
cohort of 57 subjects. The cells were examined in
undifferentiated state and following adipocyte
differentiation (AD) during 10 days.
(A) Measurement of pAKT to total AKT in cell
lysates of lean and obese BM-MSCs in undiffer-
entiated and following AD differentiation using
Immunoplex method (Gowan et al., 2007) (n = 10).
(B) Representative western blots showing insulin-
stimulated (100 nM, 15 min) phosphorylation of
AKT (p-S473AKT) and total AKT in undifferentiated
and AD differentiated BM-MSCs (n = 8 per group).
(C) Densitometry evaluation of western blots
measuring insulin stimulation (100 nM) of AKT as
p-S473-AKT to total AKT in AT-MSCs in undiffer-
entiated and AD differentiated condition in lean
and obese subjects (n = 8 per group).
(D) Representative western blots of p-S473-AKT to
total AKT in lean and obese AT-MSCs.
(E and F) Gene expression profile represented
as fold change (F.C.) of gene expression of (E)
inflammatory genes (IL1B and TNFA) and (F) adi-
pocytic marker genes (PPARG, CEBPA, FABP4,
ADIPOQ, INSR, IRS1) in lean and obese AT-MSC
(n = 10).
Data are presented as mean ± SEM; *p < 0.05 and
**p < 0.01, lean versus obese (two-tailed unpaired
Student’s t test).
See also Figure S2.of Wei et al. (2014) corroborates our hypothesis, as it showed
that mice with enhanced insulin signaling in bone are protected
from severe systemic insulin resistance phenotype. It is thus
plausible that BM maintenance of insulin responsiveness in
obese patients allows storage of fat in BM and thus serves as
protective mechanism against severe insulin resistance.
IR and LEPRAreBiomarkers for Hypermetabolic State of
BM-MSCs
As shown above, obese BM-MSC cultures were enriched for
LEPR+ and IR+ cells compared with lean BM-MSCs. To study
the in vivo relevance of the in vitro data, we determined the
expression profile of LEPR+ and IR+ cells using in situ hybridiza-
tion in human iliac crest bone biopsies obtained from healthy do-
nors (Figures 4A and 4B). Both IR+ and LEPR+ cells were more2056 Cell Reports 27, 2050–2062, May 14, 2019abundant in yellow marrow areas packed
with adipocytes compared with areas of
red marrow filled with hematopoietic
cells (Figures 4A and 4B). To study the
functional capacity of the cells, we sorted
IR+/ and LEPR+/ populations of hBM-
MSCs and examined their differentiation
potential (Figures S3A and S3B). IR+
and LEPR+ cells exhibited higher AD
differentiation capacity (Figures 4C–4F),
while IRandLEPRcellsweremoreeffi-
cient at OB differentiation (Figures 4G–4J), which was altered in
INSR-small interfering RNA (siRNA) and LEPR-siRNA transfected
cells showing lower ADand enhancedOBdifferentiation capacity
(Figures S4A–S4D). Moreover, IR+ and LEPR+ cells exhibited
higher responsiveness to insulin in culture (Figures S4E–S4H),
which was reverted with siRNA-mediated silencing of INSR and
LEPR (Figures S5A–S5D). In addition, LEPR-siRNA silencing in
BM-MSC led to impairment of leptin signaling (FiguresS5E–S5H).
Previous studies have demonstrated importance of mitochon-
drial respiration and oxidative phosphorylation (OXPHOS) in
regulation of adipogenesis (Shyh-Chang et al., 2013) and adipo-
cyte commitment, whereas osteoblast commitment is associ-
ated with glycolysis (Guntur et al., 2018). Thus, we investigated
the bioenergetic profile of IR+ and LEPR+ sorted cells (Figures
4K and 4L). Using Seahorse technology employing the Mito
Figure 4. IR+ and LEPR+ as Markers for
Metabolically Active Adipocytic Progenitor
Cells
Insulin receptor positive (IR+) and leptin receptor
positive (LEPR+) cells were sorted using fluores-
cence-activated cell sorting (FACS) from cultured
hBM-MSCs. The cells were examined at baseline
and during in vitro adipocyte (AD) and osteoblast
(OB) differentiation.
(A and B) Representative pictures of in situ hy-
bridization (red) of (A) INSR and (B) LEPRmRNA in
human iliac crest bone biopsies of healthy donors.
Arrowheads mark IR+ and LEPR+ expressing cells
in the yellow marrow (scale bars, 25 mm).
(C and D) Representative pictures of Nile red
staining for mature adipocytes in IR+ and IR cells
(C) (scale bar, 100 mm) and in LEPR+ and LEPR
cells (D) sorted from hBM-MSCs (scale bar,
100 mm).
(E) Adipocyte differentiation of IR+ and IR sorted
cells: quantification of Nile red staining for mature
adipocytes (left panel) and gene expression of
adipocytic marker genes (PPARG, CEBPA,
FABP4, ADIPOQ) following AD differentiation (right
panel).
(F) Adipocyte differentiation of LEPR+ and LEPR
sorted cells: quantification of Nile red staining for
mature adipocytes (left panel) and gene expres-
sion of adipocytic marker genes (PPARG, CEBPA,
FABP4, ADIPOQ) following AD differentiation (right
panel).
(G and H) Representative pictures of alkaline
phosphatase (ALP) staining for mature osteoblasts
in (G) IR+ and IR cells (scale bar, 400 mm) and (H)
in LEPR+ and LEPR cells sorted (scale bar,
400 mm).
(I) Osteoblast differentiation of IR+ and IR cells:
quantification of ALP activity represented as fold
change over non-induced cells (left panel) and
gene expression of osteoblastic genes (RUNX2,
ALPL, COL1A1, BGLAP) following OB differentia-
tion (right panel).
(J) Osteoblast differentiation of LEPR+ and LEPR
cells: quantification of ALP activity represented as
fold change over non-induced cells (left panel) and
gene expression of osteoblastic genes (RUNX2,
ALPL, COL1A1, BGLAP) following OB differentia-
tion (right panel).
(K and L) Bioenergetic profiling of (K) IR+ and IR cells and (L) LEPR+ LEPR cells in Mito stress test measuring mitochondrial oxygen consumption rate (OCR).
Oligo, oligomycin; FCCP, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; R&A, rotenone and antimycin A.
Data are presented as mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001, positive versus negative cells (two-tailed
unpaired Student’s t test).
See also Figures S4 and S5.stress test, we measured cellular OXPHOS reflecting mitochon-
drial function by determining the oxygen consumption rate
(OCR). Undifferentiated IR+ and LEPR+ cells exhibited higher
OCRs, which correlates with their AD commitment phenotype
(Figures 4K and 4L).
IR+ and LEPR+ Cells Exhibit Accelerated Senescence
Phenotype
High levels of OCR and increased oxidative respiratory capacity
lead to increased production of reactive oxygen species (ROS),
which may promote accelerated cellular senescence (Manola-gas, 2010). To examine this hypothesis in IR+ and LEPR+ hBM-
MSCs, markers of cellular senescence were determined.
Compared with IR and LEPR cells, IR+ and LEPR+ cells
showed increased expression of senescence-associated genes
(TP53, CDKN2A, CDKN1A) and oxidative stress markers
(HMOX1, SOD2, ALDH1A1) (Figures 5A and 5B) as well as higher
expression of senescence-associated secretory phenotype
(SASP) markers that play a role in creating senescence microen-
vironment (Farr et al., 2016, 2017) (Figures S6A and S6B). In addi-
tion, we determined the levels of cellular senescence-associated
marker b-galactosidase (b-gal) (Itahana et al., 2013), whichCell Reports 27, 2050–2062, May 14, 2019 2057
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Figure 5. Cultured IR+ and LEPR+ Cells
Exhibit Accelerated Senescence Phenotype
IR+ and LEPR+ cells were FACS-sorted from
cultured hBM-MSCs.
(A and B) Gene expression of senescence-asso-
ciated markers (TP53, CDKN2A, CDKN1A) and
oxidative stress markers (HMOX1, SOD2,
ALDH1A1) in (A) IR+ and IR cells and (B) in
LEPR+ and LEPR cells.
(C and D) Senescence-associated b-galactosi-
dase (b-gal activity) in (C) IR+ and IR cells and (D)
in LEPR+ and LEPR cells (n = 3).
(E and F) ROS production following 1 h treatment
withH2O2 (100 mM) in (E) IR+ and IR cells and (F) in
LEPR+ andLEPR cells (n = 3). Data are presented
as mean ± SEM from three independent experi-
ments. *p < 0.05, **p < 0.01, and ***p < 0.001,
positive versus negative cells (two-tailed unpaired
Student’s t test).
(G) Representative b-gal staining in BM-MSC
cultures established from lean and obese sub-
jects. Red arrows mark blue senescent cells
(scale bar, 40 mm) (n = 3).
(H) b-gal activity in BM-MSCs from lean and
obese subjects (n = 3).
(I) ROS production following 1 h treatment with
H2O2 (100 mM) in cultured BM-MSCs from lean
and obese subjects (n = 3).
(J and K) Gene expression of senescence-asso-
ciated markers (TP53, CDKN2A, CDKN1A) (J) and
oxidative stress markers (HMOX1, SOD2,
ALDH1A1) (K) in cultured BM-MSCs from lean and
obese subjects (n = 3). Data are presented as
mean ± SEM; *p < 0.05, **p < 0.01, and ***p <
0.001, lean versus obese (two-tailed unpaired
Student’s t test).
(L–N) Effect of treatment with IR antagonist (S961)
on AD differentiation and metabolic activity in
cultured hBM-MSCs.
(L) Densitometry evaluation of western blot
measuring insulin stimulation (100 nM) of AKT as p-
S473-AKT to total AKT following S961 treatment
(100 nM).
(M) Gene expression of adipocytic marker genes
(PPARG, CEBPA, FABP4, ADIPOQ, INSR, LPL)
following S961 treatment (100 nM) during AD differentiation.
(N) Bioenergetic profiling of BM-MSCs treated with or without S961 (1 mM) in Mito stress test measuring mitochondrial function (OCR). Oligo, oligomycin; FCCP,
carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; R&A, rotenone and antimycin A (n = 3). Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, and
***p < 0.001, non-treated versus S961-treated (two-tailed unpaired Student’s t test).
See also Figure S6.confirmed the presence of high levels of b-gal activity, suggesting
an increased number of senescent cells in IR+ and LEPR+ cul-
tures (Figures 5C and 5D). These findings were accompanied
by increased ROS production in IR+ and LEPR+ cultures (Figures
5E and 5F). Because obese BM-MSC cultures were enriched for
IR+ and LEPR+ cells, we examined the presence of an acceler-
ated cellular senescence phenotype. Obese BM-MSC cultures
contained higher number of senescent b-gal+ cells, exhibited
higher b-gal activity and increased ROS production (Figures
5G–5I) as well as increased gene expression levels of cellular
senescence and oxidative stress markers (Figures 5J and 5K).
Because our results suggest that the presence of enhanced in-
sulin signaling in obese BM-MSCs leads to a hyper-activated2058 Cell Reports 27, 2050–2062, May 14, 2019metabolic phenotype,we testedwhetherblocking insulin signaling
in BM-MSCs reverses this phenotype. Treatment of BM-MSCs
with IR blocker (S961) led to decreased AKT phosphorylation
anddecreasedADdifferentiationcapacity (Figures5Land5M;Fig-
ure S6C).Moreover, inhibiting insulin signaling byS961decreased
the OCR of BM-MSCs (Figure 5N). These results were further
confirmed by siRNA-mediated silencing of INSR in BM-MSC
cultures that resulted in lower metabolic activity and OCR,
decreasedgeneexpression levelsofADmarkers,aswell assenes-
cenceandoxidative stressmarkers in INSR-siRNAcomparedwith
SCR-siRNA transfected cells (Figures S6D and S6E).
A number of studies have reported that enhanced insulin
signaling leads to an accelerated senescence phenotype. In
hematopoietic stem cells overexpressing IR, increased prolifer-
ation and differentiation capacity of the progenitor cells leading
to cellular senescence have been observed (Kharas et al.,
2010). Moreover, the basal IR tyrosine kinase activity is upregu-
lated during oxidative stress associated with a cellular senes-
cence phenotype (Schmitt et al., 2005). Furthermore, the role
of enhanced insulin signaling in age-related degenerative dis-
eases has been demonstrated in animals deficient in IR that
exhibited downregulation of cellular metabolism and oxidative
stress signaling and extended healthy lifespan (Dro¨ge, 2005).
Limitations of the Study
Our study had some limitations. The study was performed inmen
as a continuation of preclinical studies performed in male mice
by others and us (Doucette et al., 2015; Scheller et al., 2016; Ten-
cerova et al., 2018). However, a similar study investigating
cellular changes in a female cohort is needed. We have exam-
ined the hypothesis of presence of intrinsic defects in BM-
MSCs using cultured cells. Although in vitro culture conditions
may influence cellular phenotype, a number of previous studies
have demonstrated that in vitro cultured preadipocytes, adipo-
cytes, or muscle cells maintained metabolic characteristics of
the donor (Jiang et al., 2013; Kase et al., 2015; Tchkonia et al.,
2006; van Tienen et al., 2011). This clinical study was performed
in BM-MSCs obtained from the iliac crest, which is recognized as
a standard sampling site for bone biopsies in healthy subjects
and is considered to reflect the status of skeletal bone remodel-
ing. Even though obesity affects the skeleton in a site-specific
manner, using the iliac crest as a source of bone biopsy has
the advantage of being a standardized site that is used by the
majority of investigators, allowing comparison of results.
Overall Perspective
Our study provides an understanding of obesity-associated
bone fragility as mediated by enhanced insulin signaling and
enrichment for AD progenitor cells in the BM microenvironment.
These changes lead to increased glucose use and enhanced
mitochondrial OXPHOS, producing ROS and causing BM-MSC
stem cell exhaustion and the creation of a senescent BM micro-
environment conducive to bone fragility. An increased number of
senescent cells has been reported in AT-MSCs of obese sub-
jects (Tchkonia et al., 2010), and we extend these findings to
BM-MSCs. Our data identify increased insulin signaling in BM-
MSCs as a target for a potential tailored therapy in obesity and
T2D-associated bone fragility and support a previous study by
Farr et al. (2017) showing that elimination of senescent cells in
mice prevented age-related bone loss.
What is the mechanism of maintenance of BM insulin
signaling in the context of obesity-associated peripheral insulin
resistance? Our study provides a plausible explanation, as it
demonstrates the presence of multiple factors: the increased
number of IR-positive progenitors, increased expression of
IR, the known presence of a BM barrier (Mangialardi et al.,
2013; Shadduck et al., 1989), and the protection of the inflam-
matory response by the hematopoietic cells (Tencerova et al.,
2018) possibly by the anti-inflammatory and immunosuppres-
sive characteristics of BM-MSCs being part of the innate
immune response (Marigo and Dazzi, 2011). Teleologically,absence of insulin resistance in BM-MSC may represent an
adaptive response to meet the energy requirement needed
for defense against infection (Wolowczuk et al., 2008). Finally,
our findings can explain the presence of low bone turnover in
obese and T2D patients leading to accumulation of fatigue
damage, decreased bone material quality, and increased risk
for bone fragility (Burr et al., 1997).
Recent studies in healthy individuals revealed positive biolog-
ical effects of metabolic slowing following a caloric restriction
program for 2 years (Heilbronn and Ravussin, 2003; Redman
et al., 2018) and provide an interesting perspective for the pre-
vention of accelerated aging observed in metabolically active
organs, including the skeletal system. Beneficial effects of
caloric restriction or selective insulin inhibition on bone stem
cell functionality and bone fragility in obese and T2D patients
remain to be determined.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
Participants including lean (n = 19), overweight (n = 15) and obese (n = 20) healthy men (age 33 ± 2 years; body mass index (BMI)
21-41 kg/m2) were recruited from the local community. Exclusion criteria were known metabolic bone disease, known diabetes
mellitus and use of medication or concomitant diseases that influence bone and fat metabolism such as glucocorticoids and anabolic
drugs as well as impaired renal and hepatic function. The study was performed according to the Declaration of Helsinki and was
approved by the Regional Committees on Health Research Ethics for Southern Denmark (Project-ID: S-20150013). All participants
signed informed consent prior to participation in the study.
Isolation and culture of bone marrow stromal stem cells from bone marrow aspirates
Bone marrow samples were obtained by aspiration of 10-15mL from the iliac crest after infiltration of the area with local anesthetic
(lidocaine, 10 mg/mL), in a 20-mL syringe and mixed 1:1 with heparin (100 U/mL). Low-density mononuclear cells were isolated
through centrifugation with a Lymphoprep density gradient (density = 1.077 ± 0.001 g/cm2) and then selected through the process
of plastic adherence. Cells were then cultured at 1x105 cells/cm2 (1x106 cells per chamber slide) in Minimal Essential Media (MEM)
containing 10% fetal bovine serum (FBS, GIBCO) incubated at 5% CO2 at 37
C and then nourished by completely changing the
medium once a week along with passage at 70% confluence. Cultured cells were sub-cultured and further studied in differentiation
conditions to induce adipogenesis and osteogenesis, respectively.
Isolation and culture of adipose-derived stromal cells (AT-MSCs) from needle biopsy
A needle biopsy (size 12G) from the subcutaneous abdominal adipose tissue was obtained after the OGTT to isolate adipose-derived
MSC (AT-MSCs). AT-MSCs were isolated according to a previous publication (slightly modified) (Rossmeislova´ et al., 2013) following
digestions with Collagenase I (200 U/mL), centrifugation steps, red blood cells (RBC) lysis and washing steps with PBS. Initially, the
cells were plated in culture dishes in DMEM/F12 culture medium with 10% fetal bovine serum (FBS), incubated at 5% CO2 at 37
C
and then nourished by completely changing the medium once every three days along with a passage at 80% confluence. After
expansion in vitro the cells were sub-cultured and further studied in differentiation conditions to induce adipogenesis.
METHOD DETAILS
Clinical investigations
Bone mass, body composition and metabolic characteristics were analyzed using DXA scan, oral glucose tolerance test (OGTT) and
standard biochemical analysis.
Oral glucose tolerance test (OGTT)
A 2 hour OGTT was performed with 75 g of glucose load. Venous blood was drawn from an antecubital vein at time 0, 30 and 120 min
after the glucose administration to determine plasma glucose (ABL 800Flex, Radiometer, Denmark) and serum levels of insulin and
C-peptide (Cobas e411 analyzer, Roche Diagnostics, Denmark). The OGTT was performed after an overnight fast of at least ten
hours. Additionally, fasting venous blood was collected for subsequent biochemical analyses and stored at 80C. HOMA-IR
(homeostasis model assessment of the insulin resistance index) was calculated as follows: (fasting insulin (mU/L)_fasting glucose
(mmol/L))/22.5.e2 Cell Reports 27, 2050–2062.e1–e6, May 14, 2019
DXA scans
Total lean and total fat mass were measured by DXA (Hologic Discovery, Waltham, Massachusetts, USA), and these data were used
to calculate fat distribution. Areal bone mineral density (aBMD) was measured at the lumbar spine (L1-L4), total hip and the femoral
neck using DXA.
Biochemical analyses
Biochemical analyses (hormone and lipid profiles) were performed by the hospital laboratory in blood samples drawn in fasting state.
Serum levels of adiponectin and leptin were measured by ELISA kit (ALPCO and R&D Biosystems, respectively). Measurement of
fasting serum procollagen type I amino-terminal propeptide (P1NP) (CV 10%, LOD 5 ng/mL) and C-telopeptide of type I collagen
(CTX) were both performed by validated routine methods (Cobas e602 analyzer, Roche Diagnostics, Denmark), the limit of detection
(LOD) for P1NP and CTXwere 5ng/mL and 0.01 ng/mL, respectively, and the interassay coefficients of variation (CV) on two levels for
both methods were 10% or lower. Levels of tartrate-resistant acid phosphatase 5b (Trap5b) were measured by a commercially avail-
able immunocapture enzyme assay (MicroVue TRAP5b, Quidel, San Diego, USA) according to themanufacturer’s protocol (CV 10%,
LOD 0.2 U/L). Quantitative analysis of inflammatory cytokines/chemokines (U-plex: IL-1a; IL-1RA, MCP-1, SDF-1a and V-plex IL-1b,
IL-4, IL-6, IL-8, IL-10, TNF-a) in plasma samples was performed using Immunoplex kits (MesoScale) and aMESOQuickPlex machine
(MesoScaleDiscovery).
Flow cytometry
BM-MSC were immunophenotyped using a panel of MSC cell markers (see the list in Table S5). Adherent cells were removed from
flasks using 0.05% trypsin EDTA, incubated with Fc-blocking solution followed by incubation with pre-conjugated antibodies
according to manufacturer recommendations. The flow cytometry was performed by BD LSR II (BD Biosciences) and analyzed by
Kaluza 1.1 analysis software.
For the cell sorting experiments, hBM-MSCswere incubated with Fc-blocking solution followed by incubation with pre-conjugated
antibodies either LEPR-PE (Miltenyi) or IR- PE antibody (BD Bioscience) and were run through a BD FACS Aria III (BD Bioscience).
Representative gating scheme is shown in Figures S3A and S3B. LEPR+/ and IR+/ subpopulations were collected and sub-
cultured in vitro for subsequent cellular analyses.
Cells proliferation
Primary BM-MSCswere plated in 6-well plates at a density of 10,000 cells/well in a standard growthmedium supplementedwith 10%
FBS. Cells number was evaluated every day from 1 to 14. Cells were washed with PBS, harvested by trypsinization and manually
counted in triplicate using Burker-Turk counting chambers.
Colony forming unit-fibroblast (CFU-f) assay
For assessment of CFU, cells were plated in p0 at a density of 0.5 million and 1 million cells in T75 flask. After 14 days, colonies
displaying more than 50 cells were counted using Crystal Violet staining (Sigma-Aldrich).
In vitro differentiation
Adipocyte differentiation
Cells were plated at a density of 30000 cells/cm2. Adipocytic induction media DMEM, containing 10% FBS, 10% Horse serum
(GIBCO), 100 U/mL penicillin (GIBCO), 100 mg/mL streptomycin (GIBCO), 100 nM dexamethasone (Sigma-Aldrich), 0.25 mM 3-iso-
butyl-1-methyxanthine (IBMX), 1 mMBRL (Sigma-Aldrich), 3 mg/mL Insulin (Sigma-Aldrich), was changed every other day for 10 days.
Oil Red O staining
At day 10 of adipocyte differentiation, cells were fixed in 4% paraformaldehyde for 10 min at room temperature then stained with Oil
Red O (Sigma-Aldrich) to visualize the lipid content. Briefly, cells were rinsed in 3% isopropanol solution and stained with filtered Oil
Red O solution (0.5 g in 100% isopropanol) for 1 h at room temperature (RT).
Osteoblast differentiation
The cells were plated at a density of 20000 cells/cm2 in alpha MEM medium (GIBCO) containing 10% FBS, 100 U/mL penicillin
(GIBCO), 100 mg/mL streptomycin (GIBCO). Osteoblast induction media was composed of base medium supplemented with
10 mM B-glycerophosphate (Sigma-Aldrich), 10 nM dexamethasone (Sigma-Aldrich), 50 mg/mL Vitamin C (Sigma-Aldrich) and
50 mg/mL Vitamin D (Sigma-Aldrich) replaced media one day after the seeding. The medium was changed every other day for
10 days.
Alizarin Red staining
Mineralized matrix formation at day 10 of osteoblast differentiation, was measured using Alizarin red staining (Abdallah et al., 2006).
Cells were fixed with 70% ice-cold ethanol for 1 h at 20C before addition of AR-S (40 mM; Sigma-Aldrich) dissolved in distilledCell Reports 27, 2050–2062.e1–e6, May 14, 2019 e3
water (pH 4.2). The cells were stained for 10 min at RT. The level of calcium deposition was quantified by elution of AR-S following
incubation in 10%cetylpyridinium chloride (Sigma-Aldrich) for 1 h at RT. The absorbance of the eluted dyewas assessed at 570 nm in
a FLU OstarOmega plate reader.
Alkaline phosphatase (ALP) activity assay
Cells were incubated with naphthol AS-TR phosphate solution containing Fast Red TR (Sigma-Aldrich) as described previously
(Abdallah et al., 2006). Alkaline phosphatase activity was measured using p-nitrophenyl phosphate (Fluka Chemie) as substrate
(Qiu et al., 2007).
Insulin responsiveness of BM-MSCs and AT-MSCs
Undifferentiated and AD differentiated cells were starved overnight in serum free media. The following day the cells were stimulated
with 100nM insulin (Sigma Aldrich) for 15 min and then harvested for protein used in subsequent analyses.
Senescence-associated b-galactosidase (b-gal) activity assay
SA-b-gal Activity 96-well assay kit was used (Cell Biolabs, Inc-USA, Catalog Number CBA-231) to determine the cellular senescence
by measuring SA-b-Gal activity using a fluorometric substrate according to the manufacture protocol. All reagents were prepared
fresh on the day of the assay. Cells were seeded at density 1.5x104 cells /well in black 96-well plate clear bottom. Following day
viability dye was added (10%) to the culture media and incubated in the dark at 37C for 1h. Measurement was subsequently taken
using fluorescent mode (Ex 530 nm/Em 590 nm). The results were normalized to the number of cells/well and expressed as % SA-
b-gal activity.
Senescence-associated b-galactosidase Staining
To examine the senescence in the cells we used a commercial kit for b-galactosidase staining (Cell Signaling Technology-
Netherlands, Cat# 9860). Cells were cultured in black 96-well plate clear bottom at 1.5 x104 cells /well 24 hours before the assay.
Media were removed and cells were washed with PBS, and then fixed for 10 minutes at room temperature. After fixation the cells
were rinsed with PBS and incubated with b-galactosidase staining solution (pH = 6.0) at 37◦C in dry incubator (no CO2) overnight.
The blue color as a reaction results was monitored after 12h. Images of cells were taken with inverted microscope under bright field.
Cellular Reactive Oxygen Species (ROS) Detection assay
DCFDA (2,7-dichloro-dihydro-fluorescein diacetate) (Abcam, Cambridge, MA) was used to measure the intracellular ROS levels. The
cells were seeded at 2.5x104 cells/well into a black 96 well plate with a clear bottom 24 hours before the assay. Culture media was
replaced with DMEM complete culture media without phenol red supplemented with tert-butyl hydrogen peroxide (TBHP) at 100mM
for 2 hours at 5.5%CO2 incubator and 37
C.Media with TBHPwas removed and cells were loaded with DCFDA 25mMand incubated
for 45 minutes at 37C. DCFDA was removed and experimental conditions (media with or without TBHP) were added again to the
cells. Then, the fluorescent intensity was measured at Excitation 485 nm and Emission 535 nm kinetically using microplate reader
every 1 minute for 30 minutes.
Mitochondrial stress test
IR ± and LEPR ± sorted cells and transfected hBM-MSCs were seeded at density 15 000 cells/ well in 8 multi-well plates (Agilent,
Seahorse Bioscience) and analyzed in undifferentiated condition. Oxygen consumption rate (OCR) of non-differentiated cells were
determined using an XFp Extracellular Flux Analyzer (Seahorse Bioscience) applying Mito stress test in XF media (non-buffered
DMEM containing 10 mM glucose, 4 mM L-glutamine, and 2 mM sodium pyruvate) under basal conditions and in response to oligo-
mycin (1 mM), 2 mM fluoro-carbonyl cyanide phenylhydrazone (FCCP) and 0.5 mM rotenone + 0.5 mM antimycin A. Basal OCR was
calculated by subtraction of rotenone- and antimycin A-induced OCR (1 mM of each inhibitor) to the unstimulated OCR value.
Maximal respiration was determined using FCCP (2 mM) according to Wu et al. (2007). The data were analyzed using Wave Software
(Seahorse Bioscience).
Treatment of BM-MSCs with S961 (insulin receptor antagonist)
hBM-MSCs were treated during AD differentiation with an insulin receptor antagonist at two different concentrations (10 or 100 nM)
(S961; cat.n. ABIN2876379) (www.antibodies-online.com) for 10 days. The AD differentiated cells were harvested after 10 days for
subsequent analyses.
siRNA transfection of hBM-MSCs
hBM-MSCs were transfected with the small interfering RNA (siRNA), targeting INSR (ID# s533803), LEPR (ID# s8137) as well as
non-targeting siRNA (siRNA negative control, SCR cat# 4390846) were purchased from Ambion (Life Technology Inc). siRNAe4 Cell Reports 27, 2050–2062.e1–e6, May 14, 2019
were transfected to hBM-MSCs at a final concentration of 25 nM by Lipofectamine2000 (Invitrogen) as previously described (Chen
et al., 2018) and according to the manufacturer’s instructions. Transfection cocktail was subsequently replaced after 7 hours with
normal culture media without antibiotics. 48 hours post transfection culture media was replaced with adipogenic or osteogenic dif-
ferentiation media as described above.
Treatment of transfected and sorted hBM-MSCs with insulin and leptin
hBM-MSCs were transfected with INSR-siRNA or LEPR-siRNA and Scr-siRNA as a control, day 2 post transfection, the transfected
cells and sorted cells were incubated in MEM/0.5% BSA media for 4 hours followed by insulin stimulation (100nM) for 15 minutes or
(100nM) leptin stimulation (L-4146, Sigma) for 10 minutes. Then the cells were harvested for subsequent western blot analyses.
RNA extraction and Real time qRT-PCR
RNAwas extracted using TRIzol then the QIAGENRneasyMini Kit (QIAGEN) and reverse-transcribed using a RevertAid HMinus First
Strand cDNA Synthesis Kit (Thermo Scientific). Quantitative real-time PCR was performed with an Applied Biosystems 7500
Real-Time PCR System using Fast SYBR Green Master Mix (Applied Biosystems) with specific primers (Table S6). b-actin was
used as an endogenous control. Results are expressed as delta-delta Ct values.
RNA sequencing of BM-MSCs
RNA-seq was performed on RNA isolated from BM-MSC samples from lean and obese subjects (n = 10 per group). Unstranded,
single read RNA-seq libraries were constructed from 1 mg total RNA using the NEBNext Ultra II procedure (New England Biolabs)
and sequenced on the HiSeq 1500 platform (Illumina). Sequenced reads were mapped up against a human transcriptome index,
and counted in annotated transcripts using the quasi-based mapping mode of Salmon (default parameters) (Patro et al., 2017).
The transcriptome index was build using Ensembl genome version GRCh38 and Gencode v24 annotations (both files obtained
from encodeproject.org).
The differential expression analysis was done on raw RNA-seq counts by the DESeq2 method (Love et al., 2014) comparing obese
to lean. Genes with a false discovery rate (FDR) below 0.1 were considered as differentially expressed.
Gene ontology (GO) enrichment was done by comparing the frequency of genes from a GO category in the differentially regulated
gene sets, to the frequency in the whole dataset using fisher exact tests. Shown GO categories are selected from a longer list of
significantly enriched GO-categories (p < 0.05), and are displayed as how frequent genes of the GO category are found in the differ-
entially expressed gene sets (%).
Western blot
Protein lysates were prepared using M2 lysis buffer including protease inhibitors. Protein concentration was measured using BCA
assay (Thermo Scientific). Extracts (25 mg of protein) were examined by protein immunoblot analysis by probing with antibodies
to total AKT (#9272, Cell Signaling), pSer473AKT (#4051, Cell Signaling), total ERK2 (#sc-154, Santacruz), (# pERK1/2 (#sc-7383,
Santacruz), total JAK2 (#3230S, Cell Signaling), pJAK2 (#3771S, Cell Signaling), total STAT3 (#12640s, Cell Signaling), pSTAT3
(#9145S, Cell Signaling), b-Actin (A2066, Sigma-Aldrich). Immunocomplexes were detected by enhanced chemiluminescence and
analyzed by Image Lab software (BioRad).
Multiplexed ELISA of Protein Phosphorylation
Quantitative analysis of pSer473-AKT/AKT in cell lysates of BMSC was performed using Immunoplex kits (MesoScale) and a MESO
QuickPlex machine (MesoScaleDiscovery) (Gowan et al., 2007).
In situ hybridization Analyses of Human Bone Specimens
Formalin-fixed, decalcified and paraffin-embedded bone specimens from four human healthy volunteers (2 men and 2 women; aged
27-49 years, BMI 27-38 kg/m2) were included in situ hybridization analysis. The biopsies were collected according to the Declaration
of Helsinki and approval by the Regional Committees on Health Research Ethics for Southern Denmark (Projekt ID S-20110112). All
participants signed informed consent prior to participation in the study. Paraffin sections (3.5-mm thick) were in situ hybridization us-
ing an enhanced version of the RNAScope 2.5 high definition procedure (310035, ACD Bioscience, Newark, CA, US). Sections were
rehydrated, deparaffinized and pretreated as previously (Lassen et al., 2017), and hybridized overnight at 40C with 20-ZZ-pair
probes binding either human InsR mRNA (450061, ABD Bioscience) or LepR mRNA (410381, ACD Bioscience) diluted 1:1 in probe
diluent (449819, ACD Bioscience). A negative control only hybridized with probe diluent was included. The amplification was
conducted according to the instructions provided by the manufacturer. The horse radish peroxidase was further enhanced with
digoxigenin (DIG)-labeled tyramide (NEL748001KT, PerkinElmer, Skovlunde, Denmark), which was labeled with alkaline-phospha-
tase-conjugated sheep anti-DIG FAB-fragments (11093274910, Roche, Hvidovre, Denmark) and visualized with Liquid
Permanent Red (DAKO, Glostup, Denmark). Finally, the sections were counterstained with Mayer’s Haematoxylin and mounted
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QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses
The statistical significance of the differences in the means of experimental groups (lean, overweight and obese subjects) were
determined by unpaired t test or analysis of variance (ANOVA) and Bonferroni or Tukey post hoc tests using GraphPad Prism
5.0a software. Data are presented as means ± SEM. P value < 0.05 was considered significant. All the statistical details of
experiments can be found in the figure legends.
DATA AND SOFTWARE AVAILABILITY
Due to issues related to patient confidentiality, raw RNA seq data is not currently available for a public repository. If consent and
approval are granted in the future, the raw data will be made available at that time. With specific questions related to data, please
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